These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1975 related articles for article (PubMed ID: 33547062)
1. EULAR points to consider on pathophysiology and use of immunomodulatory therapies in COVID-19. Alunno A; Najm A; Machado PM; Bertheussen H; Burmester GR; Carubbi F; De Marco G; Giacomelli R; Hermine O; Isaacs JD; Koné-Paut I; Magro-Checa C; McInnes I; Meroni PL; Quartuccio L; Ramanan AV; Ramos-Casals M; Rodríguez Carrio J; Schulze-Koops H; Stamm TA; Tas SW; Terrier B; McGonagle DG; Mariette X Ann Rheum Dis; 2021 Jun; 80(6):698-706. PubMed ID: 33547062 [TBL] [Abstract][Full Text] [Related]
2. 2021 update of the EULAR points to consider on the use of immunomodulatory therapies in COVID-19. Alunno A; Najm A; Machado PM; Bertheussen H; Burmester GR; Carubbi F; De Marco G; Giacomelli R; Hermine O; Isaacs JD; Koné-Paut I; Magro-Checa C; McInnes IB; Meroni PL; Quartuccio L; Ramanan AV; Ramos-Casals M; Rodríguez Carrio J; Schulze-Koops H; Stamm TA; Tas SW; Terrier B; McGonagle DG; Mariette X Ann Rheum Dis; 2022 Jan; 81(1):34-40. PubMed ID: 34620584 [TBL] [Abstract][Full Text] [Related]
3. Immunomodulatory therapies for SARS-CoV-2 infection: a systematic literature review to inform EULAR points to consider. Alunno A; Najm A; Mariette X; De Marco G; Emmel J; Mason L; McGonagle DG; Machado PM Ann Rheum Dis; 2021 Jun; 80(6):803-815. PubMed ID: 33589438 [TBL] [Abstract][Full Text] [Related]
4. Immunomodulatory therapies for the treatment of SARS-CoV-2 infection: an update of the systematic literature review to inform EULAR points to consider. Alunno A; Najm A; Mariette X; De Marco G; Emmel J; Mason L; McGonagle DG; Machado PM RMD Open; 2021 Oct; 7(3):. PubMed ID: 34725262 [TBL] [Abstract][Full Text] [Related]
5. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial. Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543 [TBL] [Abstract][Full Text] [Related]
6. Recommendations on the management of adult patients with rheumatic diseases in the context of SARS-CoV-2/COVID-19 infection. Colombian Association of Rheumatology. Saldarriaga Rivera LM; Fernández Ávila D; Bautista Molano W; Jaramillo Arroyave D; Bautista Ramírez AJ; Díaz Maldonado A; Hernán Izquierdo J; Jáuregui E; Latorre Muñoz MC; Restrepo JP; Segura Charry JS Reumatol Clin (Engl Ed); 2020; 16(6):437-446. PubMed ID: 32800760 [TBL] [Abstract][Full Text] [Related]
7. EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors. Kostine M; Finckh A; Bingham CO; Visser K; Leipe J; Schulze-Koops H; Choy EH; Benesova K; Radstake TRDJ; Cope AP; Lambotte O; Gottenberg JE; Allenbach Y; Visser M; Rusthoven C; Thomasen L; Jamal S; Marabelle A; Larkin J; Haanen JBAG; Calabrese LH; Mariette X; Schaeverbeke T Ann Rheum Dis; 2021 Jan; 80(1):36-48. PubMed ID: 32327425 [TBL] [Abstract][Full Text] [Related]
8. Insight in the Current Progress in the Largest Clinical Trials for Covid-19 Drug Management (As of January 2021). Panovska-Stavridis I; Ridova N; Stojanoska T; Demiri I; Stevanovic M; Stojanovska S; Ristevska T; Dimkovski A; Filipce V; Dimovski A; Grozdanova A Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2021 Apr; 42(1):5-18. PubMed ID: 33894123 [TBL] [Abstract][Full Text] [Related]
10. Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection. McCullough PA; Kelly RJ; Ruocco G; Lerma E; Tumlin J; Wheelan KR; Katz N; Lepor NE; Vijay K; Carter H; Singh B; McCullough SP; Bhambi BK; Palazzuoli A; De Ferrari GM; Milligan GP; Safder T; Tecson KM; Wang DD; McKinnon JE; O'Neill WW; Zervos M; Risch HA Am J Med; 2021 Jan; 134(1):16-22. PubMed ID: 32771461 [TBL] [Abstract][Full Text] [Related]
11. 2019 EULAR points to consider for the assessment of competences in rheumatology specialty training. Sivera F; Alunno A; Najm A; Avcin T; Baraliakos X; Bijlsma JW; Badreh S; Burmester G; Cikes N; Da Silva JA; Damjanov N; Dougados M; Dudler J; Edwards CJ; Iagnocco A; Lioté F; Nikiphorou E; van Onna M; Stones SR; Vassilopoulos D; Haines C; Ramiro S Ann Rheum Dis; 2021 Jan; 80(1):65-70. PubMed ID: 32788400 [TBL] [Abstract][Full Text] [Related]
12. EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2. Landewé RB; Machado PM; Kroon F; Bijlsma HW; Burmester GR; Carmona L; Combe B; Galli M; Gossec L; Iagnocco A; Isaacs JD; Mariette X; McInnes I; Mueller-Ladner U; Openshaw P; Smolen JS; Stamm TA; Wiek D; Schulze-Koops H Ann Rheum Dis; 2020 Jul; 79(7):851-858. PubMed ID: 32503854 [TBL] [Abstract][Full Text] [Related]
13. A randomized open-label trial to evaluate the efficacy and safety of triple therapy with aspirin, atorvastatin, and nicorandil in hospitalised patients with SARS Cov-2 infection: A structured summary of a study protocol for a randomized controlled trial. Sharma A; Sharma C; Raina S; Singh B; Dadhwal DS; Dogra V; Gupta S; Bhandari S; Sood V Trials; 2021 Jul; 22(1):451. PubMed ID: 34266452 [TBL] [Abstract][Full Text] [Related]
14. COVID-19 and the Use of Immunomodulatory Agents in Ophthalmology. Değirmenci MFK; Yalçındağ FN; Tugal-Tutkun İ Turk J Ophthalmol; 2021 Aug; 51(4):231-242. PubMed ID: 34461710 [TBL] [Abstract][Full Text] [Related]
15. Pathogenesis-directed therapy of 2019 novel coronavirus disease. Stratton CW; Tang YW; Lu H J Med Virol; 2021 Mar; 93(3):1320-1342. PubMed ID: 33073355 [TBL] [Abstract][Full Text] [Related]
16. Management of severe hyperinflammation in the COVID-19 era: the role of the rheumatologist. Papadopoulou C; Al Obaidi M; Moraitis E; Compeyrot-Lacassagne S; Eleftheriou D; Brogan P Rheumatology (Oxford); 2021 Feb; 60(2):911-917. PubMed ID: 33197261 [TBL] [Abstract][Full Text] [Related]
17. Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial. Garcia-Vicuña R; Abad-Santos F; González-Alvaro I; Ramos-Lima F; Sanz JS Trials; 2020 Sep; 21(1):772. PubMed ID: 32907638 [TBL] [Abstract][Full Text] [Related]
18. EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-CoV-2: the November 2021 update. Landewé RBM; Kroon FPB; Alunno A; Najm A; Bijlsma JW; Burmester GR; Caporali R; Combe B; Conway R; Curtis JR; Elkayam O; Gossec L; Heijstek MW; Haupt L; Iagnocco A; Isaacs JD; Juhász IÁ; Makri S; Mariette X; McInnes IB; Mehta P; Mueller-Ladner U; Schulze-Koops H; Smolen JS; Wiek D; Winthrop KL; Navarro-Compán V; Machado PM Ann Rheum Dis; 2022 Dec; 81(12):1628-1639. PubMed ID: 35197264 [TBL] [Abstract][Full Text] [Related]
19. Current and emerging immunomodulators for treatment of SARS-CoV2 infection (COVID-19). McCarthy MW Expert Opin Pharmacother; 2022 Apr; 23(5):623-628. PubMed ID: 35103549 [TBL] [Abstract][Full Text] [Related]
20. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial. Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]